EGFR and neoplasm: Cancer cells may further accumulate EGFR with gene amplification in 10–58%11,12 or a mutant EGFRvIII in up to 42% of tumors13,14, and establish a suppressive tumor microenvironment (TME)15–17, suggesting that EGFR may serve as an ideal target for drug development.